Brokerages Set Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Price Target at $3.75

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) has been given a consensus rating of “Hold” by the seven ratings firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and two have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $3.75.

HOWL has been the topic of a number of analyst reports. Wall Street Zen downgraded shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings cut shares of Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 16th.

Insider Buying and Selling

In related news, Director Luke Evnin sold 305,741 shares of Werewolf Therapeutics stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $0.70, for a total value of $214,018.70. Following the transaction, the director directly owned 1,273,008 shares of the company’s stock, valued at $891,105.60. This trade represents a 19.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Ra Capital Management, L.P. sold 416,911 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $0.35, for a total transaction of $145,918.85. Following the transaction, the insider owned 303,719 shares of the company’s stock, valued at approximately $106,301.65. This represents a 57.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 4,067,237 shares of company stock worth $2,070,189 over the last three months. 23.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Werewolf Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of HOWL. Regal Investment Advisors LLC raised its holdings in shares of Werewolf Therapeutics by 93.3% during the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after buying an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. boosted its stake in Werewolf Therapeutics by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after buying an additional 24,003 shares in the last quarter. Renaissance Technologies LLC grew its position in Werewolf Therapeutics by 48.6% in the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock valued at $429,000 after acquiring an additional 221,766 shares during the last quarter. Susquehanna International Group LLP grew its position in Werewolf Therapeutics by 16.9% in the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after acquiring an additional 13,439 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new position in Werewolf Therapeutics during the third quarter worth about $304,000. Institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Stock Performance

NASDAQ:HOWL opened at $0.37 on Friday. The stock has a fifty day moving average price of $0.41 and a 200-day moving average price of $0.62. The company has a market cap of $17.88 million, a price-to-earnings ratio of -0.30 and a beta of 0.30. Werewolf Therapeutics has a fifty-two week low of $0.27 and a fifty-two week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. Research analysts predict that Werewolf Therapeutics will post -1.08 EPS for the current fiscal year.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.